TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04 Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45 14 WEEK SSAC FINAL #1 Facility: Battelle Columbus Laboratory Chemical CAS #: TEFBINARYMIX Lock Date: 03/27/02 Cage Range: All Reasons For Removal: 25017 Scheduled Sacrifice Removal Date Range: 12/16/98 - 12/17/98 Treatment Groups: Include 001 0 NG / 0 UG Include 002 10 NG / 10 UG Include 003 100 NG /100 UG Include 005 300 NG /300 UG Include 007 1000 NG/1000 UG a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 1 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04 Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially In Study 98 86 98 98 98 Scheduled Sacrifice 16 10 16 16 16 Early Deaths Survivors Animals Examined Microscopically 10 10 10 10 10 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Liver (10) (10) (10) (10) (10) Fatty Change, Diffuse 1 [1.0] 6 [1.2] Inflammation 10 [1.0] 10 [1.0] 10 [1.0] 10 [1.0] 10 [1.2] Mixed Cell Focus 1 1 1 Necrosis 1 [1.0] Pigmentation 4 [1.0] 5 [1.0] 8 [1.0] Hepatocyte, Hypertrophy 4 [1.0] 3 [1.0] 6 [1.0] 10 [2.2] Hepatocyte, Multinucleated 7 [1.0] Pancreas (10) (10) (10) (10) (10) Basophilic Focus 2 Acinus, Atrophy 1 [1.0] 1 [2.0] ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM None ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (10) (10) (10) (10) (10) Hypertrophy 1 [2.0] 1 [1.0] 1 [1.0] Thyroid Gland (10) (10) (10) (10) (10) Follicular Cell, Hypertrophy 3 [1.0] 3 [1.0] 4 [1.0] 8 [1.4] 9 [1.3] ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 2 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04 Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (10) (10) (10) (10) (10) Atrophy 4 [3.3] 2 [3.5] 4 [3.8] 3 [3.7] 3 [3.3] Uterus (10) (10) (10) (10) (10) Metaplasia, Squamous 2 [1.0] 1 [1.0] 3 [1.0] 1 [1.0] 1 [1.0] ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Spleen (10) Pigmentation 10 [1.1] Thymus (10) (10) (10) (10) (10) Atrophy 4 [1.0] 1 [1.0] 1 [2.0] 5 [1.2] ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM None ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (10) (10) (10) (10) (10) Hemorrhage 1 [1.0] Inflammation 1 [1.0] 1 [1.0] 1 [1.0] ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 3 NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04 Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 13:11:45 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 10 NG / 100 NG / 300 NG / 1000 NG/ 0 UG 10 UG 100 UG 300 UG 1000 UG ____________________________________________________________________________________________________________________________________ URINARY SYSTEM None a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 4 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------